SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Don’t Chase American Virtual Cloud Technologies Higher
Box Inc. Stock on Track to Become a Q4 Winner
Is Ford's Revenue Enough to Juice its Stock Price?
Sweden seizes evidence at Baltic Sea pipeline leak site
US futures retreat on strong hiring, more jobs data on tap
NASDAQ:RDUS

Radius Health - RDUS Stock Forecast, Price & News

$10.08
0.00 (0.00%)
(As of 09/16/2022)
Add
Compare
Today's Range
$10.08
$10.08
50-Day Range
$10.07
$10.22
52-Week Range
$4.97
$23.00
Volume
4,802 shs
Average Volume
1.17 million shs
Market Capitalization
$480.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Radius Health MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
14.7% Downside
$8.60 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$40,401 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

1058th out of 1,075 stocks

Pharmaceutical Preparations Industry

529th out of 537 stocks

RDUS stock logo

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Stock News Headlines

Golden Age Of Merger Arb: Radius
Short Volatility Alert: Radius Health, Inc.
4 Analysts Have This to Say About Radius Health
See More Headlines
Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
Employees
293
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-14.7%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-70,180,000.00
Pretax Margin
-30.73%

Debt

Sales & Book Value

Annual Sales
$229.97 million
Book Value
($5.74) per share

Miscellaneous

Free Float
46,796,000
Market Cap
$480.01 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Mr. G. Kelly Martin (Age 63)
    CEO, Pres & Director
    Comp: $600.48k
  • Ms. Danielle Holtschlag (Age 44)
    VP of Sales & Head of U.S. Sales Channels
    Comp: $299.3k
  • Ms. Chhaya Shah (Age 58)
    Sr. VP & Chief Bus. Officer
    Comp: $631.62k
  • Dr. Stavros C. Manolagas
    Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr. (Age 90)
    DSc, M.D., Founder & Member of the Scientific Advisory Board
  • Dr. Michael Rosenblatt M.D. (Age 74)
    Founder, Board Observer & Member of Scientific Advisory Board
  • Dr. John A. Katzenellenbogen
    Founder & Member of the Scientific Advisory Board
  • Mr. Mark William Conley CPA (Age 60)
    VP, CFO, Principal Accounting Officer & Treasurer
  • Mr. Peter A. Schwartzman
    Head of Corp. Fin.
  • Ethan Holdaway
    Head of Investor Relations













RDUS Stock - Frequently Asked Questions

Should I buy or sell Radius Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings
or view top-rated stocks.

What is Radius Health's stock price forecast for 2022?

5 equities research analysts have issued twelve-month price objectives for Radius Health's shares. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.60 in the next twelve months. This suggests that the stock has a possible downside of 14.7%.
View analysts price targets for RDUS
or view top-rated stocks among Wall Street analysts.

How have RDUS shares performed in 2022?

Radius Health's stock was trading at $6.92 at the beginning of the year. Since then, RDUS stock has increased by 45.7% and is now trading at $10.08.
View the best growth stocks for 2022 here
.

When is Radius Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RDUS earnings forecast
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) released its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.35. The biopharmaceutical company earned $58.29 million during the quarter, compared to analyst estimates of $67.95 million.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How do I buy shares of Radius Health?

Shares of RDUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $10.08.

How much money does Radius Health make?

Radius Health (NASDAQ:RDUS) has a market capitalization of $480.01 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Radius Health have?

The company employs 293 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.